Moderna COVID-19 vaccine

Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India

Retrieved on: 
Tuesday, June 29, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, COVID-19, COVID-19 vaccines, Clinical trials, RNA vaccines, Medical research, Medicine, Health sciences, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Moderna, RNA vaccine, the Moderna COVID-19 Vaccine, Moderna, THE MODERNA COVID-19 VACCINE, MODERNA

Moderna is pursuing a clinical development strategy against emerging variants to proactively address the pandemic as the virus continues to evolve.

Key Points: 
  • Moderna is pursuing a clinical development strategy against emerging variants to proactively address the pandemic as the virus continues to evolve.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
  • Severe allergic reactions, including anaphylaxis, have been reported following administration of the Moderna COVID-19 Vaccine during mass vaccination outside of clinical trials.
  • Individuals who have received one dose of Moderna COVID-19 Vaccine should receive a second dose of Moderna COVID-19 Vaccine to complete the vaccination series.

Global WholeHealth Partners Corp (GWHP-OTC) Acquires Rights to Distribute & Sell a 3rd COVID-19 Vaccine - Moderna

Retrieved on: 
Tuesday, June 29, 2021
Medical research, Health sciences, COVID-19 vaccines, Clinical trials, RNA vaccines, Health, Medicine, BioNTech, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Pfizer

As with the Johnson & Johnson 8K filed on June 10, 2021, for the J&J rights, the Company filed on June 16, 2021, for Pfizer and filed for Moderna on June 25, 2021, stating that Effective June 22, 2021, Global WholeHealth Partners Corporation (the Company) was granted the rights from Nunzia Pharmaceutical Inc. (Nunzia) to distribute and sell the Moderna COVID-19 Vaccine.

Key Points: 
  • As with the Johnson & Johnson 8K filed on June 10, 2021, for the J&J rights, the Company filed on June 16, 2021, for Pfizer and filed for Moderna on June 25, 2021, stating that Effective June 22, 2021, Global WholeHealth Partners Corporation (the Company) was granted the rights from Nunzia Pharmaceutical Inc. (Nunzia) to distribute and sell the Moderna COVID-19 Vaccine.
  • The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.
  • [1]
    According to reports: With additional supply agreements under its belt, Moderna now predicts its vaccine will generate $19.2 billion by years end.
  • Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov .

Early results from a national study confirm antibody levels are stronger after receiving two doses

Retrieved on: 
Wednesday, June 23, 2021
Clinical trials, COVID-19 vaccines, COVID-19, Vaccines, Medicine, Vaccine, Moderna COVID-19 vaccine, COVID-19 vaccination in Canada

CanPath is a national population health research platform that follows the health of 330,000 volunteer Canadians (or 1% of the population).

Key Points: 
  • CanPath is a national population health research platform that follows the health of 330,000 volunteer Canadians (or 1% of the population).
  • Early results from this study show a lag in the development of antibodies after a single vaccine dose.
  • The study detected high levels of antibodies in participants with two doses of an mRNA vaccine, with levels almost twice as high as those after the first dose.
  • The Canadian Partnership for Tomorrows Health (CanPath) is Canadas largest population health study and a national platform for health research.

European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022

Retrieved on: 
Tuesday, June 22, 2021
Research, Infectious diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, COVID-19, Medical research, COVID-19 vaccines, Clinical trials, Medicine, Health sciences, RNA vaccines, BioNTech, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, Moderna, COVID-19 vaccine, the COVID-19 Vaccine Moderna, Moderna, THE COVID-19 VACCINE MODERNA, MODERNA

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has purchased an additional 150 million doses of Modernas COVID-19 vaccine, including the ability to purchase other COVID-19 vaccine candidates from Modernas pipeline.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has purchased an additional 150 million doses of Modernas COVID-19 vaccine, including the ability to purchase other COVID-19 vaccine candidates from Modernas pipeline.
  • This purchase brings the European Commissions confirmed order commitment to 460 million doses.
  • Under the terms of the agreement, delivery of Modernas updated variant booster vaccine candidate will begin in 2022.
  • Purchase under this agreement is subject to regulatory approval of the booster vaccine candidates by the European Medicines Agency (EMA).

OCUGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 19, 2021
Legal, Professional services, COVID-19 vaccines, Clinical trials, RNA vaccines, Medicine, Health sciences, Health, Covaxin, BioNTech, Medical research, Emergency Use Authorization, Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine

Investors have until August 17, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 17, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On May 26, 2021, Ocugen announced that it planned to submit to the FDA an Emergency Use Authorization (EUA) application for COVAXIN, a COVID-19 vaccine, in June 2021.
  • Shares of Ocugen fell by more than 24% in intraday trading on the same day, based on this news.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Moderna Reaffirms Commitment to Job Creation in Massachusetts

Retrieved on: 
Friday, June 18, 2021
Biotechnology, Technology, Professional services, Other Health, Health, General Health, Pharmaceutical, Other Technology, Infectious diseases, Other Professional Services, Human resources, Branches of biology, Life sciences, Biology, RNA, Medical research, Molecular genetics, Moderna, Messenger RNA, Vaccine, Moderna COVID-19 vaccine

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reaffirmed its commitment to job creation in Massachusetts.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reaffirmed its commitment to job creation in Massachusetts.
  • In the last year, Moderna created more than 650 new jobs at its manufacturing facility in Norwood, Massachusetts.
  • On June 15, Moderna was awarded a tax incentive from the Massachusetts Life Sciences Center (MLSC) based on its commitment to hire 155 new full-time equivalent employees in 2021 and retaining that headcount through 2025.
  • I would like to thank the Massachusetts Life Sciences Center and the Baker-Polito Administration for this recognition of our commitment to creating new, high-tech employment opportunities in Massachusetts.

U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine

Retrieved on: 
Wednesday, June 16, 2021
Research, Other Health, General Health, Pharmaceutical, Healthcare reform, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Health, Public policy, Government, Other Science, COVID-19, Medical research, COVID-19 vaccines, Clinical trials, RNA vaccines, Medicine, Health sciences, BioNTech, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, Moderna, RNA vaccine, the Moderna COVID-19 Vaccine, Moderna, THE MODERNA COVID-19 VACCINE, MODERNA

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Modernas COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Modernas pipeline.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Modernas COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Modernas pipeline.
  • As of June 14, Moderna has supplied 217 million released doses of the vaccine to the U.S. government.
  • The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
  • Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.

Direct Relief Facilitates Donations of 1.75 Million COVID-19 Vaccine Doses to Mexico, Belize, Bolivia and Paraguay

Retrieved on: 
Tuesday, June 15, 2021
COVID-19 vaccines, Clinical trials, Vaccines, Medicine, RNA vaccines, Health sciences, Medical research, Adenoviridae, FedEx, Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, COVID-19 vaccine

The deliveries include 1.35 million doses from the U.S. to Mexico and a total of 400,000 doses from Mexico to Belize, Bolivia and Paraguay.

Key Points: 
  • The deliveries include 1.35 million doses from the U.S. to Mexico and a total of 400,000 doses from Mexico to Belize, Bolivia and Paraguay.
  • A FedEx flight arrived today at Toluca International Airport near Mexico City with 1.35 million doses of Johnson & Johnson's single-dose COVID-19 vaccine.
  • The U.S. government sent the vaccine to Mexico with support from Direct Relief, which arranged to fly the doses from the U.S. to Mexico via its longstanding relationship with FedEx.
  • Since January 2020, Direct Relief has provided 38 million doses of temperature-sensitive medication requiring refrigerated shipping to 60 countries.

Dr. Paul Burton to Join Moderna as Chief Medical Officer

Retrieved on: 
Monday, June 14, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Nucleic acids, Life sciences, Branches of biology, Medical research, RNA, Moderna, Janssen, Messenger RNA, Arcturus Therapeutics, Moderna COVID-19 vaccine

Moderna , Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Paul Burton, M.D., Ph.D., F.A.C.C, M.R.C.S will join the Company as Chief Medical Officer, effective July 6, 2021.

Key Points: 
  • Moderna , Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Paul Burton, M.D., Ph.D., F.A.C.C, M.R.C.S will join the Company as Chief Medical Officer, effective July 6, 2021.
  • Pauls extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company, said Stphane Bancel, Chief Executive Officer of Moderna.
  • Since March 2020, he served as Chief Global Medical Affairs Officer of Janssen Pharmaceuticals where he was responsible for Janssens worldwide medical affairs strategy and execution.
  • I am honored to take on the role of Chief Medical Officer at Moderna.

Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland

Retrieved on: 
Monday, June 14, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Medical Supplies, COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, Medical research, RNA vaccines, Moderna COVID-19 vaccine, COVID-19 vaccine, Vaccine, Moderna, COVID-19 vaccination in Switzerland, the Moderna COVID-19 Vaccine, Moderna, THE MODERNA COVID-19 VACCINE, MODERNA

We are pleased to announce that we have submitted an authorization application for our COVID-19 vaccine with Swissmedic for use in adolescents in Switzerland, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We are pleased to announce that we have submitted an authorization application for our COVID-19 vaccine with Swissmedic for use in adolescents in Switzerland, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents.
  • In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.
  • The vaccine efficacy in the nearly 2,500 adolescents who received the Moderna COVID-19 vaccine was observed to be 100% when using the same case definition as in the Phase 3 COVE study in adults.